bevacizumab + liposomal irinotecan + capecitabine

This combination treatment regimen is an investigational second-line therapy for advanced metastatic colorectal cancer (mCRC). It consists of **bevacizumab**, a recombinant humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor (VEGF), thereby inhibiting tumor angiogenesis; **liposomal irinotecan**, a formulation of the topoisomerase I inhibitor irinotecan encapsulated in long-circulating liposomal nanoparticles to enhance drug delivery to tumor tissues; and **capecitabine**, an oral fluoropyrimidine carbamate that undergoes a three-step enzymatic conversion to 5-fluorouracil (5-FU) within the body, primarily in tumor tissue. The regimen is being evaluated in clinical trials (such as NCT05555901) led by investigator Liu Huang in China, where it serves as a comparator arm against fruquintinib-based combinations for patients who have failed first-line oxaliplatin-based chemotherapy.

Other names

bevacizumab + irinotecan liposome + capecitabinebevacizumab + nal-IRI + capecitabinebevacizumab + liposomal irinotecan + capecitabine-Liu Huang-colorectal cancer